Deutsche Bank upgraded Intuitive Surgical from Sell to Buy despite a 33% stock drop in 2026, citing its attractive valuation with a forward P/E ratio of 35, well below its five-year average of 54. The company maintains a strong market position with over 12,000 da Vinci robotic surgery systems installed, which provides resilience against competition from rivals and emerging technologies. Analysts see this as a potential buying opportunity in the robotic surgery sector, expecting Intuitive Surgical to retain leadership despite market pressures from Chinese competitors and AI threats. The upgrade signals renewed confidence in the company’s growth prospects and innovation in medical technology.
Intuitive Surgical is rated a Hold with a price target of $426.65, implying a 9.17% upside. The company's growth potential lies in untapped Ambulatory Surgery Center (ASC) procedure volume and the limited threat from remanufacturing, which currently ...
Intuitive Surgical's stock has fallen over 30% this year, yet the company continues to grow its installed base of surgical robots and recurring revenue from instruments and services. The da Vinci system fleet expanded 12% in Q2 2026, with recurring r...
